Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Ongoing Initiated Mar 4, 2025 (2 years ago)

Gabapentin Capsules

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Cross Contamination

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Gabapentin Capsules, USP 400 mg, Rx Only, Packaged in a) 500-count bottles, NDC 62756-139-05; b) 1000-count bottles, NDC 62756-139-04; Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Ltd. Halol-Baroda Highway, Halol-389 350, Gujarat, India.

Affected NDCs 62756-0139-04 62756-0139-05

Compare with the code on your package — it is the most precise check available.

Drug: Gabapentin Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
gabapentin
NDC 62756-0139
400 mg/1 Capsule
Oral
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Sun Pharmaceutical Industries INC
NDC code
62756-139-05
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0312-2025 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm.

Other Gabapentin recalls

See all
Class II · Moderate risk

Gabapentin Capsules

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Ongoing Impurity / degradation The Harvard Drug Group LLC NDC 0904-6665-61 D-0031-2026
Class II · Moderate risk

Gabapentin Capsules

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Ongoing Impurity / degradation The Harvard Drug Group LLC NDC 0904-6665-61 D-0030-2026
Class II · Moderate risk

Gabapentin Capsules

Defective container; blister packaging inadequately sealed.

Ongoing Packaging defect The Harvard Drug Group LLC NDC 55154-3363-0 D-0508-2025
Class II · Moderate risk

Gabapentin Capsules

Defective container; blister packaging inadequately sealed.

Ongoing Packaging defect The Harvard Drug Group LLC NDC 0904-6665-61 D-0507-2025

Other recalls by Sun Pharmaceutical Industries INC

All 2025 recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026
Class II · Moderate risk

Perampanel CIII Tablets

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Ongoing Labeling / mix-up Sun Pharmaceutical Industries INC NDC 51672-4206-6 D-0628-2026